Credit: Canva
Low-dose CT chest scans could help detect pneumonia in at-risk patients while exposing them to only small amounts of radiation, a new study has found. The research, published in Radiology: Cardiothoracic Imaging, shows that ultra-low-dose scans can effectively detect pneumonia in patients with compromised immune systems, enabling doctors to treat the infection before it becomes life-threatening. According to the researchers, these scans expose patients to just 2% of the radiation dose used in a standard CT scan.
"This study paves the way for safer, AI-driven imaging that reduces radiation exposure while preserving diagnostic accuracy,” lead researcher Dr Maximiliano Klug, a radiologist with the Sheba Medical Center in Ramat Gan, Israel, said in a news release. He added that CT scans are the gold standard for detecting pneumonia but there are concerns regarding the risk posed by repeated exposure to radiation. There is a solution- ultra-low-dose CT scan. However, the problem is that these scans can be grainy and hard to read, researchers said.
Study Gives Solution To This
To overcome that, Klug's team developed an AI program that could help "de-noise" low-dose scans, making them sharper and easier to read. Between September 2020 and December 2022, 54 patients with compromised immune systems who had fevers underwent a pair of chest CT scans -- a normal dose scan and an ultra-low-dose scan. The AI program cleaned up the low-dose scan, and then both sets of images were given to a pair of radiologists for assessment. Radiologists had 100% accuracy in detecting pneumonia and other lung problems with the AI-cleaned low-dose scans, but 91% to 98% accuracy in examining the scans that hadn’t been improved through AI, results show.
"This pilot study identified infection with a fraction of the radiation dose," Klug said. "This approach could drive larger studies and ultimately reshape clinical guidelines, making denoised ultra-low dose CT the new standard for young immunocompromised patients.
How Can You Detect Pneumonia?
Pneumonia is a lung infection that causes the air sacs in the lungs to fill with fluid or pus and can be caused by bacteria, viruses, or fungi. The symptoms can range from milk to severe, which includes:
Coughing with or without cough
Fever
Chills
Trouble breathing
Chest pain, especially when breathing deeply or coughing
Sweating or chills
Rapid heart rate
Loss of appetite
Bluish skin, lips, and nails
Confusion.
How to detect Pneumonia in coughing newborns and toddlers?
Pneumonia can severely affect newborns and young children as their lungs are comparatively more sensitive. As per Dr Goyal, young children can cough for various reasons including seasonal infections and tonsillitis, which is very common in this age group. But if they look visibly irritable and have poor sleep patterns, then parents must reach out to an expert. "I am not saying that parents must visit a hospital but any local paediatrician would be able to detect pneumonia in your kid.
Credit: iStock
The US Food and Drug Administration's independent advisory panel has recommended approval of Moderna's mRNA-based influenza vaccine for older adults.
The panel backed the vaccine, known as mFLUSIVA, for adults aged 50 years and older, concluding that its benefits outweigh its risks.
If ultimately approved by the FDA, mFLUSIVA would become the world's first messenger RNA (mRNA) vaccine for seasonal influenza. The development could provide a new tool against a disease that causes an estimated 15 million to 60 million illnesses, 180,000 to 700,000 hospitalizations, and 17,000 to 75,000 deaths annually in the United States, according to data from the US Centers for Disease Control and Prevention (CDC).
The recommendation came from the Vaccines and Related Biological Products Advisory Committee (VRBPAC), which reviews vaccine applications and advises the FDA.
The meeting marked the committee's first review of a new vaccine application since 2023 and could lead to the first vaccine approval under the second Trump administration.
In a unanimous vote, all nine panel members supported the use of Moderna's mFLUSIVA vaccine for adults aged 50 to 64 years, as well as for those aged 65 years and older—the age group that had previously raised regulatory concerns.
Also read: No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine
However, before the vaccine can be made available for the upcoming flu season, it must receive formal FDA approval and be recommended by the CDC's Advisory Committee on Immunization Practices (ACIP). The CDC advisory panel has not recently convened due to ongoing legal and administrative challenges. An FDA decision on the vaccine is expected by August 5.
According to Moderna, the vaccine outperformed standard-dose flu vaccines in adults aged 50 to 64 years.
In a large clinical trial involving approximately 40,000 adults aged 50 years and older, Moderna's mRNA vaccine reduced influenza cases by about 27% compared with another routinely used flu vaccine.
The company also conducted a smaller study among adults aged 65 years and older. The results showed that mFLUSIVA generated a strong immune response compared with a high-dose influenza vaccine already recommended for seniors.
FDA adviser Dr. Anna Durbin of Johns Hopkins University described the immune-response data as "very compelling," adding that "the vaccine looks very promising," AP News reported.
Read More: Sickle Cell Disease: Why India Must Add Curative Treatment to Meet Its 2047 Elimination Goal
Like Moderna's COVID-19 vaccines, mFLUSIVA uses messenger RNA technology. Rather than introducing a weakened or inactivated virus, mRNA vaccines deliver genetic instructions that help the body's cells produce proteins that trigger an immune response. This approach allows vaccines to be updated more quickly and may improve protection against evolving viruses.
Moderna's data showed no major safety concerns.
The most commonly reported side effects included:
These reactions were generally temporary and are commonly seen with many vaccines. However, they occurred somewhat more frequently than with currently available flu vaccines. FDA reviewers noted that this is typical of mRNA-based vaccines.
If approved, Moderna plans to conduct a large post-approval study involving approximately 400,000 adults aged 65 years and older.
Half of the participants will receive the mRNA vaccine, while the other half will receive one of the currently recommended flu vaccines for seniors. The study is expected to continue across two influenza seasons.
A Moderna executive said the company hopes to make the vaccine available to patients in time for the upcoming flu season, Reuters reported.
Credit: PIB
Indian President Droupadi Murmu, on the occasion of World Sickle Cell Day 2026, today expressed confidence that the country can eradicate sickle cell disease well before the 2047 target.
Addressing the International Sickle Cell Day commemoration at Omkareshwar, Madhya Pradesh, President Murmu noted that the National Sickle Cell Anaemia Elimination Mission, launched in 2023, has so far "screened seven crore people, ranging from newborns to those up to 40 years of age."
Calling it "one of the largest initiatives for genetic disease screening in the world," she added that the mission has detected sickle cell disease "in approximately 2.5 lakh people so far, and over 20 lakh carriers of the disease have also been identified."
"Through the collective strength and active engagement of all states, we will succeed in achieving our national goal of eradicating sickle cell-related diseases from the country well before the year 2047," the President said.
The President highlighted three key dimensions of the mission:
She also stressed the need for collective efforts to raise awareness and eliminate the genetic blood disorder, particularly among tribal communities.
Also read: Sickle Cell Disease: Why India Must Add Curative Treatment to Meet Its 2047 Elimination Goal
Sickle cell disease is an inherited blood disorder that affects the shape and function of red blood cells. Instead of being round and flexible, the red blood cells become sickle- or crescent-shaped, making it difficult for them to move smoothly through blood vessels.
The chronic single-gene disorder causes a debilitating systemic syndrome characterized by chronic anemia, acute painful episodes, organ infarction, chronic organ damage, and a significant reduction in life expectancy.
"Sickle cell disease (SCD) is one of India’s most pressing inherited blood disorders, with an estimated 1 in 86 births among tribal and disadvantaged groups affected," Dr Manisha Madkaikar is Director - ICMR-National Institute for Research on Blood and Immune Disorders – Mumbai, told HealthandMe.
Children living with the condition often experience repeated hospital visits, missed school days and limitations in daily activities. Parents frequently face emotional distress, financial strain and the challenge of managing a lifelong medical condition.
Read More:No Women Aged 20-24 Died of Cervical Cancer in England Over Five Years, Thanks to HPV Vaccine
The National Sickle Cell Anaemia Elimination Program, introduced in the Union Budget 2023, focuses on addressing the significant health challenges posed by sickle cell disease, particularly among tribal populations in the country.
Implemented across 17 high-focus states, the programme aims to improve care and outcomes for sickle cell disease patients while reducing the prevalence of the disorder. The states are Gujarat, Maharashtra, Rajasthan, Madhya Pradesh, Jharkhand, Chhattisgarh, West Bengal, Odisha, Tamil Nadu, Telangana, Andhra Pradesh, Karnataka, Assam, Uttar Pradesh, Kerala, Bihar, and Uttarakhand.
Implemented in mission mode under the National Health Mission (NHM), the program aims to eliminate sickle cell genetic transmission by 2047.
Over a three-year period from 2023-24 to 2025-26, the program targets screening approximately seven crore people, promoting early diagnosis and intervention on a large scale.
Credit: @DNIGabbard/X
Did COVID-19 emerge naturally or from a laboratory leak? Nearly seven years after the pandemic began in late 2019, and despite more than 7.1 million confirmed deaths worldwide and numerous investigations, there is still no definitive answer about the virus's origins.
Now, Tulsi Gabbard, on her last day as the Director of National Intelligence, US, has reignited the debate by alleging that Anthony Fauci, who led the scientific and medical response to the COVID-19 pandemic in America, funded research at China's infamous Wuhan Institute of Virology that contributed to the pandemic.
"The COVID-19 pandemic caused tremendous hardship and pain for millions of Americans and countless people around the world," Gabbard said in a statement.
"After years of lies, censorship, and cover-ups, the American people deserve transparency, truth, and accountability."
According to Gabbard's office, the materials were released following a year-long declassification review conducted by the Office of the Director of National Intelligence (ODNI) as part of President Trump's transparency initiative.
During the review, officials reportedly gathered testimony from intelligence community whistleblowers who alleged they faced retaliation for challenging official assessments of the virus's origins.
Gabbard said the testimony revealed a pattern of suppressing dissenting views, discouraging debate, and sidelining evidence that conflicted with prevailing intelligence assessments.
Also read: COVID-19 Vaccination Reduced Risk of Heart Attacks and Strokes in Elderly by 40%: Study
According to Gabbard, the newly declassified communications and documents reveal that
Read More: 1 in 6 Americans May Be Suffering From Long COVID, Study Finds
Importantly, the declassified materials also include testimony from whistleblowers who claim analysts supporting the lab-leak theory faced professional consequences. These include:
Read: COVID Pandemic Left 55,000 Cancer Cases Undiagnosed In 7 Nations, Including Australia and the UK
Gabbard said these allegations have been referred to the intelligence community's inspector general for further review.
Whether the allegations lead to congressional hearings, legal action, or additional independent review remains uncertain.
Any conclusions will depend on careful examination of the documents, corroborating evidence, and responses from those named in the allegations. Fauci is yet to comment on the allegations.
© 2024 Bennett, Coleman & Company Limited